Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
X4 Pharmaceuticals Inc
(NQ:
XFOR
)
0.5190
+0.0188 (+3.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about X4 Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
June 24, 2024
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
May 09, 2024
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday!
Via
InvestorPlace
XFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024
May 07, 2024
XFOR stock results show that X4 Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder
April 29, 2024
FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to...
Via
Benzinga
Exposures
Product Safety
Recap: X4 Pharmaceuticals Q4 Earnings
March 21, 2024
Via
Benzinga
X4 Pharmaceuticals's Earnings Outlook
March 20, 2024
Via
Benzinga
Recap: X4 Pharmaceuticals Q3 Earnings
November 09, 2023
Via
Benzinga
Earnings Outlook For X4 Pharmaceuticals
November 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
April 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
March 21, 2024
Via
Benzinga
XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023
March 21, 2024
XFOR stock results show that X4 Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
December 11, 2023
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the...
Via
Benzinga
What 5 Analyst Ratings Have To Say About X4 Pharmaceuticals
May 05, 2023
Via
Benzinga
X4 Pharmaceuticals: Q1 Earnings Insights
May 04, 2023
Via
Benzinga
Earnings Scheduled For March 21, 2024
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 11, 2023
Via
Benzinga
A Preview Of X4 Pharmaceuticals's Earnings
May 03, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 11, 2023
Via
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 11, 2023
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
Via
InvestorPlace
Earnings Scheduled For November 9, 2023
November 09, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
August 11, 2023
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
August 11, 2023
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
August 10, 2023
Via
Benzinga
Oracle And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
June 13, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. SunCar Technology Group Inc. (NASDAQ: SDA) shares jumped 31.2% to $22.13...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
May 17, 2023
Via
Benzinga
Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
August 10, 2023
Gainers Edible Garden AG Incorporated (NASDAQ: EDBL) shares jumped 58% to $1.88 after the company reported better-than-expected second-quarter financial results.
Via
Benzinga
X4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of Infections
May 17, 2023
X4 Pharmaceuticals Inc (NASDAQ: XFOR) highlighted new data from a Phase 3 clinical trial of once-daily, oral mavorixafor in
Via
Benzinga
Earnings Scheduled For August 10, 2023
August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via
Benzinga
Earnings Scheduled For May 4, 2023
May 04, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.